



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

112

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/084,471	05/22/1998	PATRICIA D. MURPHY	S371.31.US02	5585
9629	7590	10/05/2004	EXAMINER	
MORGAN LEWIS & BOCKIUS LLP 1111 PENNSYLVANIA AVENUE NW WASHINGTON, DC 20004			MYERS, CARLA J	
		ART UNIT	PAPER NUMBER	
		1634		

DATE MAILED: 10/05/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/084,471	MURPHY ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Carla Myers	1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

1) Responsive to communication(s) filed on 08 July 2004.  
 2a) This action is FINAL.      2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

4) Claim(s) 61-84 and 87-101 is/are pending in the application.  
 4a) Of the above claim(s) 62-84 and 87-94 is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 61 and 95-101 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date <u>6/1/01</u> .	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input checked="" type="checkbox"/> Other: <u>FASTDB sequence comparisons (28 sheets)</u>

**DETAILED ACTION**

1. This action is in response to the amendment filed July 8, 2004. Applicants arguments and amendments have been fully considered but are not persuasive to overcome all grounds of rejection. All rejections/objections not reiterated herein are hereby withdrawn. This action is made final.

***Election/Restrictions***

2. Claims 62-84 and 87-94, as well as the subject matter of claim 61(b), are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the response of October 22, 2001. In this response, Applicants elected the invention of claim 61(a), nucleic acids comprising a BRCA2 gene containing a thymidine at a position in exon 15 corresponding to nucleotide 171 of SEQ ID NO: 2.

Claims 85 and 86 have been cancelled. Claims 61 and newly added claims 95-101 have been examined herein. Claims 62-84 and 87-94 are withdrawn from consideration.

***Claim Objections***

3. Claim 96 is objected to because of the following informalities:

In claim 96, “nucleic acid molecule of of claim 61” should read “nucleic acid molecule of claim 61.”

***Claim Rejections - 35 USC § 112***

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 61 and 95-101 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A. Claims 61 and 95-101 are indefinite over the recitation of "corresponding" because this is not an art recognized term and the specification does not provide a clear definition for this term. It is not clear if "corresponding" refers to the identical nucleotide position, a complementary nucleotide position or a nearby nucleotide position.

Additionally, the claims do not clearly define the variation with respect to the overall BRCA2 gene. That is, defining the sequence variation with respect to a position in SEQ ID NO: 2 does not clearly define the variation with respect to the claimed nucleic acid comprising the BRCA2 gene. The claims should be amended to clarify the location of the variation with respect to exon 15 and the BRCA2 gene.

It is noted that in the response filed July 8, 2004, Applicants did not specifically address this rejection. Accordingly, the rejection is maintained for the reasons stated above.

**THE FOLLOWING CONSTITUTE NEW GROUNDS OF REJECTION NECESSITATED BY APPLICANTS AMENDMENTS TO THE CLAIMS:**

B. Claims 61 and 95-101 are indefinite and confusing because the claim recites the language of "selected from the group consisting of," however, the claim does not recite a group. Rather, the claim recites only a single nucleotide variation. This rejection

may be overcome by amendment of the claims to recite, for example, "containing a nucleotide variation wherein the nucleotide variation is a thymidine at a position..."

***Claim Rejections - 35 USC § 102***

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 61 and 95-101 are rejected under 35 U.S.C. 102(b) as being anticipated by Holt (U.S. Patent No. 5,891,857; cited in the IDS).

Holt teaches isolated BRCA2 nucleic acids having a T at a nucleotide position which corresponds to position 199 of SEQ ID NO: 2 (see sequence comparison printout of present SEQ ID NO: 2 and SEQ ID NO: 3 of Holt - particularly position 7804 in SEQ ID NO: 3 of Holt). The recitation in the claims of "a thymidine at a position in exon 15 corresponding to nucleotide 199 of SEQ ID NO: 2" does not clarify the position of the thymine relative to the full length nucleic acid that is claimed. Since Holt teaches a sequence in which there is a T at a position that corresponds to position 199 of SEQ ID NO: 2, Holt is considered to teach the claimed nucleic acids. Further, Holt (see, for example, column 5) teaches cloning the BRCA2 gene into a vector and transforming host cells with vectors containing the BRCA2 gene. Holt also teaches methods of making recombinant BRCA2 proteins wherein the methods comprise transforming host cells with vectors comprising the BRCA2 nucleic acid of SEQ ID NO: 3 and fragments

thereof and synthesizing BRCA2 proteins. Accordingly, Holt anticipates the claimed invention.

6. Claims 61 and 95-101 are rejected under 35 U.S.C. 102(a) as being anticipated by Futreal (U.S. Patent No. 6,045,997; cited in the IDS).

Futreal teaches isolated BRCA2 nucleic acids having a T at a nucleotide position which corresponds to position 199 of SEQ ID NO: 2 (see sequence comparison printout of present SEQ ID NO: 2 and SEQ ID NO: 1 of Futreal - particularly position 1399 in SEQ ID NO: 1 of Futreal). The recitation in the claims of "a thymidine at a position in exon 15 corresponding to nucleotide 199 of SEQ ID NO: 2" does not clarify the position of the thymine relative to the full length nucleic acid that is claimed. Since Futreal teaches a sequence in which there is a T at a position that corresponds to position 199 of SEQ ID NO: 2, Futreal is considered to teach the claimed nucleic acids. Further, Futreal (see, for example, column 11) teaches cloning the BRCA2 gene into a vector and transforming host cells with vectors containing the BRCA2 gene. Futreal also teaches methods of making recombinant BRCA2 proteins wherein the methods comprise transforming host cells with vectors comprising the BRCA2 nucleic acid of SEQ ID NO: 3 and fragments thereof and synthesizing BRCA2 proteins. Accordingly, Futreal anticipates the claimed invention.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carla Myers whose telephone number is (571) 272-0747. The examiner can normally be reached on Monday-Thursday from 6:30 AM-5:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (571)-272-0782.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Application/Control Number: 09/084,471  
Art Unit: 1634

Page 7

Carla Myers  
September 22, 2004

*Carla Myers*  
CARLA J. MYERS  
PRIMARY EXAMINER

Best Local Similarity 97.9%; Pred. No. 2.7e-50; Matches 187; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 26 TAGATTATATAAAGTCTTCAAGATGCCAGACATACAGGATATCGAAATTAAAGAGA 85  
 Db 6589 TAGATTATATAAAGTCTTCAAGATGCCAGACATACAGGATATCGAAATTAAAGAGA 6648

Qy 86 AACAAAGGCAACGGCTCTTCCAGCCAGCTGTCTATCTTGAAAAAACATCCACTC 145  
 Db 6649 AACAAAGGCAACGGCTCTTCCAGCCAGCTGTCTATCTTGAAAAAACATCCACTC 6708

Qy 146 TGCTCTGAATCTCTGAAAAGCAGTCAGTAGGAGGCCAAGTTCCTCGGTGTTCTCAT 205  
 Db 6709 TGCTCTGAATCTCTGAAAAGCAGTCAGTAGGAGGCCAAGTTCCTCGGTGTTCTCAT 6768

Qy 206 AACAGGTATGT 216  
 Db 6769 AACAGGTCTAT 6779

RESULT 4  
 US-08-603-753D-3  
 Sequence No. 5892857—  
 GENERAL INFORMATION:  
 APPLICANT: HOLT, JEFFREY T.  
 APPLICANT: JENSEN, ROY A.  
 APPLICANT: PAGE, DAVID L.  
 APPLICANT: KING, MARY-CLAIRE  
 APPLICANT: SZABO, CSILLA I.  
 APPLICANT: JETTON, THOMAS L.  
 APPLICANT: ROBINSON-BENION, CHERYL L.

TITLE OF INVENTION: CHARACTERIZED BRCA1 AND BRCA2  
 TITLE OF INVENTION: PROTEINS AND THERAPEUTIC METHODS BASED ON  
 NUMBER OF SEQUENCES: 29  
 ADDRESS: ARLES A. TAYLOR, JR.  
 STREET: SUITE 1401, UNIVERSITY TOWER, 3100 TOWER  
 CITY: DURHAM  
 STATE: NORTH CAROLINA  
 COUNTRY: USA  
 ZIP: 27707

COMPUTER READABLE FORM:  
 COMPUTER: IBM PC/XT/AT compatible  
 OPERATING SYSTEM: Windows 3.1  
 SOFTWARE: WORD PERFECT 6.1 and ASCII  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/603,753D  
 FILING DATE: 20 FEB 1996  
 CLASSIFICATION: 514

PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: U.S. 08/373,799  
 FILING DATE: 17 JAN 1995  
 ATTORNEY/AGENT INFORMATION:  
 NAME: ARLES A. TAYLOR, JR.  
 REGISTRATION NUMBER: 39,395  
 REFERENCE DOCKET NUMBER: 1242/2

TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (919) 493-8000  
 TELEX: (919) 419-0383

INFORMATION FOR SEQ ID NO: 3:  
 LENGTH: 11283  
 TYPE: nucleic acid  
 STRANDEDNESS: double  
 TOPOLOGY: linear  
 MOLECULE TYPE: cDNA to mRNA  
 HYPOTHETICAL: no

ANTI-SENSE: no  
 ORIGINAL SOURCE: Homo sapiens sapiens  
 INDIVIDUAL ISOLATE:  
 DEVELOPMENTAL STAGE: adult  
 TISSUE TYPE: female breast  
 CELL TYPE: normal and cancerous breast cells  
 CELL LINE: MCF-7  
 ORIGINELLE: EG  
 IMMEDIATE SOURCE:  
 LIBRARY: cDNA library derived from human  
 CLONE: obtained using published sequence  
 POSITION IN GENOME:  
 CHROMOSOME SEGMENT: unknown  
 MAP POSITION: unknown  
 UNITS: unknown  
 FEATURE:  
 NAME/KEY: BRCA2  
 LOCATION:  
 IDENTIFICATION METHOD:  
 OTHER INFORMATION: gene encoding BRCA2 protein  
 PUBLICATION INFORMATION:  
 AUTHORS: Wooster, R. et al.  
 TITLE: Identification of the breast cancer  
 susceptibility gene BRCA2  
 JOURNAL: Nature  
 VOLUME: 379  
 PAGES: 789-792  
 DATE: 1995  
 RELEVANT RESIDUES IN SEQ ID NO: 3  
 US-08-603-753D-3

Query Match 84.7%; Score 184.6%; DB 2; Length 11283;  
 Best Local Similarity 97.9%; Pred. No. 3.3e-50;  
 Matches 187; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 26 TAGATTTATACAGTCTTCAAGCCAGAGATAACAGGATATCGAAATTAAAGAGA 85  
 Db 7629 TAGATTTATACAGTCTTCAAGCCAGAGATAACAGGATATCGAAATTAAAGAGA 7688

Qy 86 AACAAAGGCAACGGCTCTTCCAGCCAGCTGTCTATGGTATCTGGATTCCTCCTC 145  
 Db 7689 AACAAAGGCAACGGCTCTTCCAGCCAGCTGTCTATGGTATTCCTCCTCCTC 7748

Qy 146 TGCCCTGAAATCTCTGAAAGCAGCTGTAGGAGCCAGTGCCTCTGCGTGTCTCTATA 205  
 Db 7749 TGCCCTGAAATCTCTGAAAGCAGCTGTAGGAGCCAGTGCCTCTGCGTGTCTCTATA 7808

Qy 206 AACAGGTATGT 216  
 Db 7809 AACAGGTCTAT 7819

RESULT 5  
 US-09-099-753-3  
 Sequence No. 3, Application US/09099753  
 Patent No. 6149903  
 GENERAL INFORMATION:  
 APPLICANT: HOLT, JEFFREY T.  
 APPLICANT: JENSEN, ROY A.  
 APPLICANT: PAGE, DAVID L.  
 APPLICANT: KING, MARY-CLAIRE  
 APPLICANT: SZABO, CSILLA I.  
 APPLICANT: JETTON, THOMAS L.  
 APPLICANT: ROBINSON-BENION, CHERYL L.  
 APPLICANT: THOMPSON, MARILYN E.  
 TITLE OF INVENTION: CHARACTERIZED BRCA1 AND BRCA2  
 TITLE OF INVENTION: CHARACTERIZED BRCA1 AND BRCA2  
 TITLE OF INVENTION: PROTEINS AND SCREENING AND THERAPEUTIC METHODS BASED ON  
 TITLE OF INVENTION: CHARACTERIZED BRCA1 AND BRCA2 PROTEINS.  
 NUMBER OF SEQUENCES: 29  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: ARLES A. TAYLOR, JR.  
 STREET: SUITE 1401, UNIVERSITY TOWER, 3100 TOWER

FEATURE: NAME/KEY: CDS  
LOCATION: 79..242  
US-08-755-587-31

Query Match 97.8%; Score 213.2; DB 3; Length 722;  
Best Local Similarity 98.6%; Pred. No. 5.1e-60;  
Matches 215; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 TTTTGCTAAGATTATTCTGATGATTAAGTCAAGTCAGCCAGAT 60  
Db 49 TTTTGCTAAGATTATTCTGATGATTAAGTCAAGTCAGCCAGAT 108  
Qy 61 ATACAGGATATGCCATTAGAGAAACAAGCAAAGGCAAGGGT 120  
Db 109 ATACAGGATATGCCATTAGAGAAACAAGCAAAGGCAAGGCAAT 168  
Qy 121 CTGATCTGCAAAACATCCACTCGCTCGATACTCTCTGAAGCAGCTTAGGGC 180  
Db 169 CTGATCTGCAAAACATCCACTCGCTCGATACTCTCTGAAGCAGCTAGGGC 228  
Qy 181 CAAGTCCCTCTCGTGTCTCATAAAAGGATGTT 218  
Db 229 CAAGTCCCTCTCGTGTCCATAAAAGGATGTT 266

RESULT 2  
US-08-755-587-1  
Sequence 1, Application US/08755587  
Patent No. 604597

GENERAL INFORMATION:  
APPLICANT: Futreal, Phillip A  
APPLICANT: Wooster, Richard F  
APPLICANT: Stratton, Michael R  
APPLICANT: Ashworth, Alan  
APPLICANT: Stratton, Michael R  
TITLE OF INVENTION: Materials and methods relating to the BRCA2 cancer  
TITLE OF INVENTION: Identification and sequencing of the BRCA2 cancer  
TITLE OF INVENTION: Susceptibility gene and uses thereof.  
NUMBER OF SEQUENCES: 222  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Bell Seltzer Park & Gibson  
STREET: 310 UCB Plaza, 3605 Glenwood Avenue, PO Drawer 31107  
CITY: Raleigh  
STATE: NC  
COUNTRY: USA

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)

CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/755,587  
FILING DATE: 25-NOV-1996  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: GB 9523959.6  
FILING DATE: 23-NOV-1995  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: GB 9525555.0  
FILING DATE: 14-DEC-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Kenneth D Sibley  
REGISTRATION NUMBER: 31,665  
REFERENCE/DOCKET NUMBER: 5405-135  
FILING DATE: 28-AUG-1996  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1917 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA

US-08-755-587-1  
Query Match 84.7%; Score 184.6; DB 3; Length 7240;

RESULT 3  
US-08-755-587-15  
Sequence 15, Application US/08755587  
Patent No. 6045997

GENERAL INFORMATION:  
APPLICANT: Futreal, Phillip A  
APPLICANT: Wooster, Richard F  
APPLICANT: Stratton, Michael R  
APPLICANT: Stratton, Michael R  
TITLE OF INVENTION: Materials and methods relating to the BRCA2 cancer  
TITLE OF INVENTION: Identification and sequencing of the BRCA2 cancer  
NUMBER OF SEQUENCES: 222  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Bell Seltzer Park & Gibson  
STREET: 310 UCB Plaza, 3605 Glenwood Avenue, PO Drawer 31107  
CITY: Raleigh  
STATE: NC  
COUNTRY: USA

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)

CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/755,587  
FILING DATE: 25-NOV-1996  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: GB 9523959.6  
FILING DATE: 23-NOV-1995  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: GB 9525555.0  
FILING DATE: 14-DEC-1995  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: GB 9617961.9  
FILING DATE: 28-AUG-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Kenneth D Sibley  
REGISTRATION NUMBER: 31,665  
REFERENCE/DOCKET NUMBER: 5405-135  
FILING DATE: 28-AUG-1996  
SEQUENCE CHARACTERISTICS:  
LENGTH: 7240 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA

US-08-755-587-15  
Query Match 84.7%; Score 184.6; DB 3; Length 7240;